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Objective: To better understand risk factors for pneumonia hospitalizations in people with
impaired lung function.
Methods: We analyzed longitudinal data from participants in the Atherosclerosis Risk in
Communities Study (ARIC) and the Cardiovascular Health Study (CHS). We limited our analysis
to 20,375 participants aged 45 and older at baseline. We stratified the sample based on
prebronchodilator baseline lung function data, according to modified GOLD criteria, including
a ‘‘restrictive’’ category (FEV1/FVC > 70% and FVC< 80%). We defined ‘‘pneumonia’’ as
a hospitalization with a pneumonia discharge diagnosis (ICD-9 codes 480e486) within 36
months. We used Cox proportional hazard models to determine pneumonia risk associated with
COPD stage, adjusting for age, sex, race, smoking status and comorbid disease (diabetes
mellitus or cardiovascular disease at the baseline examination).
Results: Pneumonia hospitalization risk was associated with older age, male gender, comorbid
conditions, smoking status, and level of lung function impairment. Overall, people with normal
lung function had the lowest pneumonia hospitalization rate (1.5 per 1000 person-years) and
thosewithGOLD stage3or 4COPDhad thehighest rate (22.7per 1000person-years). After adjust-
ing for other potential confounding factors, GOLD stages 3 or 4 and 2 COPD were associated with
an increased riskofpneumonia (hazard ratio [HR] 5.65, 95%confidence interval [CI] 3.29, 9.67and
2.25 (1.35, 3.75), respectively) relative to normal lung function.
Conclusion: COPDseverity (GOLDstage) is an important and independentpredictor ofpneumonia
hospitalizations in this cohort.
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Pneumonia remains an important cause of morbidity and
mortality in the United States, accounting for more than 5.
Chronic obstructive pulmonary disease and hospitalizations 225million cases, 1.3 million hospitalizations, and 60,000
deaths annually.1e4 Pneumonia is particularly problematic
in the elderly and among people with underlying diseases,
such as chronic obstructive pulmonary disease (COPD),
diabetes mellitus, and cardiovascular disease.4 In a review
of 2.3 million US pneumonia hospitalizations among people
65 years and older during the years 2000e2002, Fry et al
found that 57% had prevalent cardiac disease, 47% had
COPD, and 20% had diabetes mellitus.4 Overall in-hospital
mortality in this study, among patients with pneumonia,
was 13.8%.4 In a separate study, Holguin et al found that
over the period of 1996e2001, the in-hospital mortality
among patients with COPD and pneumonia was double that
of patients with pneumonia only (38% vs. 18%) and COPD
was associated with a three-fold increase in the risk of
comorbid pneumonia (14% vs. 4%).5
We used a modification of the Global Initiative on
Obstructive Lung Disease (GOLD) classification criteria,6,7
incorporating a classification for restrictive disease,8 to
examine the association between impaired lung function at
baseline and the occurrence of a hospitalization related to
pneumonia in a cohort of US adults aged 45 and older
comprised of participants in the Atherosclerosis Risk in
Communities Study (ARIC)9 and the Cardiovascular Health
Study (CHS).10
Methods
For this analysis we combined data from the CHS and ARIC
cohorts, both of which were population-based NIH cohorts
initiated in the late 1980s to study risk factors for the
development and progression of heart disease and stroke.
These cohorts included subjects of different ages (65 years
and older for CHS and 45e64 years old for ARIC) and had
comprehensive evaluations including lung function and
longitudinal follow-up. Combining these two cohorts into
one larger study population provides data over a wider age
range better reflecting the US adult population.
Study population: CHS
The original CHS cohort of 5201 men and women was
selected using Medicare eligibility lists provided by the US
Health Care Financing Administration for four communities:
Forsyth County, North Carolina; Pittsburgh, Pennsylvania;
Sacramento County, California; and Washington County,
Maryland during the period from May 1989 to May 1990.10
CHS participants underwent pulmonary function testing
during a baseline clinical examination and provided infor-
mation on the history of respiratory symptoms and diag-
noses, BMI, smoking history, and medical history. Study
protocols were approved for the protection of human
subjects. Details of the CHS are published elsewhere.10 Our
analysis was limited to CHS participants who provided
baseline information on respiratory symptoms, underwent
pulmonary function testing at the baseline examination,
and for whom follow-up data were available.
Study population: ARIC
The ARIC cohort of 15,792 men and women was initiated in
1986 as a longitudinal, population-based study of theetiology and clinical sequelae of atherosclerosis. Study
protocols were approved for the protection of human
subjects. Details of the ARIC study are published else-
where.9 Our analysis was limited to ARIC participants aged
45e64 years, who provided baseline information on
respiratory symptoms, who underwent pulmonary function
testing at the baseline examination, and for whom follow-
up data were available.
Pulmonary function data
Spirometry was conducted using a volume displacement,
water-sealed spirometer. At least three acceptable spi-
rograms were obtained from a minimum of five forced
expirations. The best single spirogram was identified by
a computer and confirmed by a technician. Quality
assurance was provided by the CHS Pulmonary Function
Center for CHS and the ARIC investigators for ARIC, and
the procedures followed contemporary American Thoracic
Society guidelines.11 Several measures of lung function
were used in this analysis: the forced expiratory volume
in 1 s (FEV1), the forced vital capacity (FVC), and the
FEV1/FVC ratio. We used prediction equations derived
from the Third National Health and Nutrition Examination
Survey to define the predicted values of FEV1 and FVC.
12
Variable definition
Age, sex, race and the highest education level obtained
were self-reported. Age was stratified into 4 year cate-
gories, race was classified as white or black, and education
level was classified as <12 years, 12 years, or more than
12 years.
Respondents with positive responses to ‘‘Have you ever
smoked cigarettes?’’ and ‘‘Do you now smoke cigarettes?’’
were classified as ‘‘ever smokers’’ and ‘‘current smokers,’’
respectively. Pack-years of cigarettes smoked were calcu-
lated for the current and former smokers. BMIwas calculated
as weight divided by the height squared (kg/m2).13
We defined a participant as having a respiratory
symptom (used to classify the GOLD 0 lung function status)
if they responded positively to any of the following ques-
tions: Do you usually have a cough? Do you usually bring up
phlegm from your chest? Does your chest ever sound
wheezy or whistling apart from colds? Do you have to walk
slower than people of your age on the level because of
breathlessness? Are you too breathless to leave the house or
breathless on dressing or undressing?
Using a modification of the criteria developed by the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD),6 we classified subjects according to their GOLD
stages of chronic obstructive pulmonary disease (COPD):
GOLD stage 3 or 4 (FEV1/FVC< 0.70 and FEV1< 50%
predicted), GOLD stage 2 (FEV1/FVC< 0.70 and FEV1 50
to <80% predicted), GOLD stage 1 (FEV1/FVC< 0.70 and
FEV1 80%), restricted (FEV1/FVC 0.70 and FVC< 80%
predicted), GOLD stage 0 (presence of respiratory symp-
toms in the absence of any lung function abnormality),
and no lung disease. GOLD stage 0 does not appear in the
most recent guideline revisions but we have included it in
our analyses as we have previously demonstrated adverse
outcomes among people in this category.8 Bronchodilator
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fication is based on the ‘‘prebronchodilator’’ level.
Subjects were classified as having diabetes if they either
reported a diagnosis of diabetes at baseline or had impaired
fasting or post glucose load glucose levels (>140) at the
examination. Subjects reporting a diagnosis of a previous
myocardial infarction, stroke, heart failure, angina, or
transient ischemic attacks were classified as having preva-
lent cardiovascular disease at the baseline examination.
Pneumonia definition
Hospitalization data were searched and events were
defined as any hospitalizations that occurred during 3 years
of follow-up after the baseline evaluation that included
a pneumonia (ICD-9 codes 480e486) discharge code.
Analysis
All analyses were conducted with SAS version 9.1 (SAS
Institute, Cary, NC), SUDAAN version 9.0 (RTI, Research
Triangle Park, NC) and SPSS version 10 (SPSS Inc, Chicago, IL).
Our primary outcome of interest in the survival models
was pneumonia hospitalization that occurred during the
first 3 years of follow-up, and the main predictor of interest
in our analysis was COPD severity defined by the modified
GOLD stage of lung function. We calculated the total
number of pneumonia hospitalizations per 1000 person-
years of follow-up for our key covariates. Cox proportional
hazard regression models were developed using the
SUDAAN procedure SURVIVAL to account for differential
follow-up in cohort participants. Time of follow-up was
used as the underlying time metric. Censoring occurred at
the date of the first pneumonia hospitalization, date of
death reported on the death certificate or date the
participant was last known to be alive on. Plots of the log-
log survival curves for each covariate were produced to
evaluate the proportional hazards assumptions. Age, sex,
race, smoking status, education level, body mass index,
diabetes status, and cardiovascular disease status were
included in the adjusted models.
Results
Wewereable to include15,414 of 15,792 (97.6%) participants
in theARICcohort and4961of 5201 (95.4%)participants in the
CHS cohort in this analysis. The demographic characteristics
of the 20,375 subjects included in the analysis are displayed
in Table 1. Overall, 534 (2.6%) subjects met the criteria for
GOLD stage 3 or 4 at baseline, and an additional 2081 (10.2%)
met the criteria for GOLD stage 2.
In the entire cohort, 214 of 20,375 subjects (1.1%) had
one or more hospitalizations with a pneumonia discharge
diagnosis during the 3-year follow-up period. Of these 214,
21 (9.8%) had one or more additional pneumonia hospital-
izations during that same 3-year period. Of the 214
subjects, 32 (15.0%) died during their final pneumonia-
related hospitalization.
The rate of pneumonia hospitalizations, per 1000
person-years, varied by age, race, sex, smoking status,
GOLD category, education level, and the presence ofcomorbid cardiovascular disease or diabetes mellitus
(Table 1). These rates, per 1000 person-years, ranged from
0.8 among people aged 50e54 years at baseline to 19.5
among people aged 80 and older (Table 1). Similarly, the
rates varied dramatically by lung function impairment from
1.5 per 1000 person-years among people with normal lung
function to 22.7 per 1000 person-years among people with
GOLD stage 3 or 4 COPD (Table 1).
In both the unadjusted and fully adjusted Cox propor-
tional hazard models (Table 2), age greater than 60 years,
male sex, current smoking status, lower education levels,
diabetes mellitus, cardiovascular disease, a BMI of <20, and
several categories of lung function impairment predicted
pneumonia hospitalization. Of note, participants with GOLD
stage 3 or 4 COPD at baseline had a much greater risk of
pneumonia during follow-up (hazard ratio [HR] 5.65, 95%
confidence interval [CI] 3.29, 9.67) compared to those with
normal lung function. Similarly, current smokers had an
increased risk of pneumonia hospitalizations (HR 2.21, 95%
CI 1.52, 3.22). The association between smoking, GOLD
category, and pneumonia hospitalizations is shown in Fig. 1
and demonstrates that the highest pneumonia hospitaliza-
tion rates occurred in current and former smokers with
GOLD stage 3 or 4 COPD (Fig. 1).Discussion
In this analysis of data from over 20,000 US adults, we found
that age greater than 60 years, male sex, current smoking
status, and the presence of GOLD stage 2 or more severe
COPD were independent predictors of pneumonia hospi-
talizations during 3 years of follow-up. In addition, the
presence of other chronic diseases including diabetes
mellitus and cardiovascular disease also conferred an
increased risk of subsequent pneumonia. Finally, we found
that the in-hospital mortality among study participants with
a pneumonia hospitalization was 15.0%.
Pneumonia hospitalizations have been trending upwards
in the US in recent years.4 The primary reason for this
appears to be aging of the population and better treatment
of chronic diseases such as COPD and cardiovascular
disease, resulting in a larger pool of at risk adults.4 While
Fry et al found an increasing trend in pneumonia hospital-
izations from 1988 to 2002, they also found a decrease in
the in-hospital mortality from 20.3% in 1988e1990 to 13.8%
in 2000e2002.4 The in-hospital mortality rate in the
combined ARIC and CHS cohorts was 15% for participants
with a pneumonia hospitalization, although our population
included adults as young as 45 at the initial evaluation and
hospitalizations during our study would have occurred in
the late 1980s and early 1990s.
The overall pneumonia hospitalization rate in our study
population was 3.9 per 1000 person-years for ages 45þ
years, which is lower than the 11.5 per 1000 person-years
reported by Jackson et al14 and the 10.1 per 1000 person-
years reported by Marston et al.15 Both of those previous
studies, however, evaluated study samples of older adults
aged 65 and older. The age-specific hospitalization rates
(per 1000 person-years) reported by Jackson et al of 4.9 for
65e69-year-olds, 6.5 for 70e74-year-olds, and 10.8 for 75e
79-year-olds are very similar to what we reported. In an
Table 1 Demographics of the studied population, from the Atherosclerosis Risk in Communities Study (1986e1989) and
Cardiovascular Health Study (1989e1990) with a follow-up for 3 years.
Total n (%) Participants with 1
pneumonia
hospitalization n (%)
Rate of pneumonia
hospitalizations,
per 1000 person-years
Age group
45e49 4108 (20.2) 10 (0.2) 0.9
50e54 4007 (19.7) 9 (0.2) 0.8
55e59 3763 (18.5) 15 (0.4) 1.3
60e64 3536 (17.4) 26 (0.7) 2.5
65e71 438 (2.2) 6 (1.4) 5.4
72e75 1682 (8.3) 28 (1.7) 6.7
76e79 1169 (5.7) 37 (3.2) 12.2
80 and older 1672 (8.2) 83 (5.0) 19.5
Sex
Female 11,302 (55.5) 92 (0.8) 3.0
Male 9073 (44.5) 122 (1.3) 5.0
Race
White 16,101 (79.0) 186 (1.2) 4.4
Black 4274 (21.0) 28 (0.7) 2.2
Smoking status
Current smoker 4968 (24.4) 60 (1.2) 4.4
Former smoker 7078 (34.7) 90 (1.3) 4.8
Never smoker 8329 (40.9) 64 (0.8) 2.8
Education (years)
<12 5014 (24.6) 80 (1.6) 6.1
12 6402 (31.4) 65 (1.0) 3.7
>12 8959 (44.0) 69 (0.8) 2.9
Diabetes
Yes 2578 (12.7) 53 (2.1) 7.4
No 17,797 (87.3) 161 (0.9) 3.4
Cardiovascular disease
Yes 3111 (15.3) 84 (2.7) 9.8
No 17,264 (84.7) 130 (0.8) 2.9
Body mass index
<20 811 (4.0) 20 (2.5) 9.7
20e24 6309 (31.0) 65 (1.0) 3.9
25e29 8137 (39.9) 90 (1.1) 4.1
30 7456 (36.6) 39 (0.8) 2.8
GOLD categorya
GOLD 3 or 4 534 (2.6) 29 (5.4) 22.7
GOLD 2 2081 (10.2) 39 (1.9) 6.9
GOLD 1 2900 (14.2) 47 (1.6) 6.0
GOLD 0 4525 (22.2) 37 (0.8) 2.9
Restricted 2879 (14.1) 31 (1.1) 4.2
Normal 7456 (36.6) 31 (0.4) 1.5
Total 20,375 214 (1.1) 3.9
a Modified Global Initiative on Obstructive Lung Disease (GOLD) stage 3 or 4 (FEV1/FVC< 0.70 and FEV1< 50% predicted), GOLD stage 2
(FEV1/FVC< 0.70 and FEV1 50 to <80% predicted), GOLD stage 1 (FEV1/FVC< 0.70 and FEV1 80%), restricted (FEV1/FVC 0.70 and
FVC< 80% predicted), GOLD stage 0 (presence of respiratory symptoms in the absence of any lung function abnormality), and no lung
disease. FEV1 is the forced expiratory volume in 1 s and FVC is the forced vital capacity.
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rate for pneumonia was 11.1 per 1000 person-years.16
We observed that older age was the strongest predictor
of pneumonia risk in this population-based cohort, whichis similar to what has been documented in other stud-
ies.4,14e16 Our findings of an increased risk for the male
sex, current smoking, diabetes mellitus, and COPD were
also similar to what was reported by Jackson et al in their
Table 2 Cox proportional hazard model results for time to
first pneumonia hospitalization in 3 years, hazard ratios
(HR) and 95% confidence intervals (CI).
Crude HR Adjusted HR
Age group
45e49 1.00 1.00
50e54 0.92 (0.38, 2.27) 0.82 (0.33, 2.03)
55e59 1.65 (0.74, 3.67) 1.32 (0.59, 2.92)
60e64 3.07 (1.48, 6.37) 2.25 (1.08, 4.70)
65e71 5.67 (2.07, 15.58) 4.10 (1.44, 11.68)
72e75 6.98 (3.39, 14.38) 5.95 (2.84, 12.46)
76e79 13.39 (6.66, 26.93) 10.69 (5.21, 21.96)
80 and older 21.78 (11.30, 41.98) 18.28 (9.17, 36.45)
Sex
Female 1.00 1.00
Male 1.67 (1.28, 2.19) 1.79 (1.30, 2.47)
Race
White 1.00 1.00
Black 0.57 (0.38, 0.85) 1.24 (0.81, 1.89)
Smoking status
Current smoker 1.58 (1.11, 2.25) 2.21 (1.52, 3.22)
Former smoker 1.66 (1.21, 2.25) 1.24 (0.89, 1.73)
Never smoker 1.00 1.00
Education (years)
<12 2.11 (1.53, 2.91) 1.43 (1.03, 2.01)
12 1.32 (0.94, 1.85) 1.45 (1.02, 2.03)
>12 1.00 1.00
Diabetes
Yes 2.34 (1.72, 3.19) 1.77 (1.26, 2.49)
No 1.00 1.00
Cardiovascular
disease
Yes 3.71 (2.82, 4.88) 2.20 (1.65, 2.94)
No 1.00 1.00
Body mass index
<20 2.43 (1.47, 4.01) 1.82 (1.08, 3.06)
20e24 1.00 1.00
25e29 1.08 (0.78, 1.48) 1.16 (0.84, 1.61)
30 0.74 (0.50, 1.10) 1.00 (0.66, 1.52)
GOLD categorya
GOLD 3 or 4 13.74 (8.29, 22.78) 5.65 (3.29, 9.67)
GOLD 2 4.61 (2.88, 7.39) 2.25 (1.35, 3.75)
GOLD 1 3.98 (2.53, 6.27) 1.43 (0.89, 2.30)
GOLD 0 1.98 (1.23, 3.19) 1.41 (0.86, 2.31)
Restricted 2.62 (1.59, 4.30) 2.52 (1.46, 4.35)
Normal 1.00 1.00
a Categories defined in Table 1.
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Figure 1 Rate of pneumonia hospitalizations, per 1000
person-years, by lung function impairment stage (categories
defined in Table 1) and smoking status.
228 D.M. Mannino et al.community-based study.14 In an observational study of the
universally insured elderly population of Quebec aged 65
and older, Ernst et al reported the rate of pneumonia
hospitalizations to be 1.9 per 100 annually,17 close to the
22.7 per 1000 annual rate of pneumonia hospitalizations
we found in GOLD stage 3 and 4 COPD (Table 1).
This analysis of the ARIC and CHS cohort populations had
certain limitations. We were only able to evaluatepneumonia hospitalizations according to the discharge
diagnoses, which may comprise 20e40% of the total pneu-
monias, thereby missing the majority of pneumonia
episodes mild enough to be treated in the clinic without
a hospital admission.2,14,18 Additionally, these pneumonias
were not independently or bacteriologically validated
leading to the potential for non-differential misclassifica-
tion which would bias any association towards a null
finding. In a prior analysis of pneumonia at one of the CHS
sites, among 138 hospitalizations for which an ICD-9 coded
for pneumonia was listed, this was confirmed clinically in
96% of cases and bacteriologically in 41% of cases.16 In
addition, we were not able to separate out pneumonias
that originated in the community from those nosocomial
infections contracted in a hospital or other health care
settings. We were not able to assess the role of recent
medication use, such as bronchodilators or corticosteroids,
as a potential risk factor for pneumonia, because the
participants’ medication use was only assessed at the
baseline survey and interval surveys and not at the time of
hospitalization.
Conclusion
Pneumonia is a common cause of hospitalizations and
mortality. Advanced age, cigarette smoking, male sex, and
the presence of chronic diseases such as COPD, cardiovas-
cular disease and diabetes mellitus were all associated with
a significant increased risk of pneumonia hospitalizations in
this large US population-based adult cohort.
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